Pfizer Inc. (PFE) Stock News
Follow the latest Pfizer Inc. (PFE) news and market headlines alongside the live PFE price. Stay informed on what's moving PFE.
News
Read Full Article - Read Full Article
Can LLY's Expanding Obesity Pipeline Sustain Its GLP-1 Leadership?
Eli Lilly has established itself as a dominant player in the obesity treatment market, with Mounjaro and Zepbound generating 65% of revenues. The company's April 2026 launch of Foundayo (oral GLP-1) recorded $281 million in sales, offering a more convenient alternative to injectable treatments. Lilly is developing next-generation therapies including retatrutide (triple-acting), eloralintide, and EloraTZP to maintain market leadership. However, competition is intensifying from Novo Nordisk and emerging biotech companies.
- Read Full Article
GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
- Read Full Article
Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight
The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.
- Read Full Article
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas, a clinical-stage biotech company specializing in protein degradation therapies, announced management participation in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company will present preliminary clinical data from early monotherapy dose escalation cohorts of ARV-393 (Zaloblideg), a PROTAC BCL6 degrader, at the 2026 American Society of Hematology Annual Meeting, including safety, pharmacokinetics, and pharmacodynamics data.
Explore More US Stocks
Data Sources and Disclosures
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to PFE, including RealStocks and Stock Futures.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.
